

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Krogulski Kenneth</u>  (Last) (First) (Middle) 2525 WEST END AVENUE SUITE 950  (Street) NASHVILLE TN 37203  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>CUMBERLAND PHARMACEUTICALS INC [ CPIX ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/20/2019	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/20/2019		P		65 <sup>(1)</sup>	A	\$5.33	161,422	D	
Common Stock	09/23/2019		P		65 <sup>(1)</sup>	A	\$5.35	164,287	D	
Common Stock	09/24/2019		P		65 <sup>(1)</sup>	A	\$5.39	164,352	D	
Common Stock	09/25/2019		P		65 <sup>(1)</sup>	A	\$5.38	164,417	D	
Common Stock	09/26/2019		P		65 <sup>(1)</sup>	A	\$5.76	164,482	D	
Common Stock	09/27/2019		P		65 <sup>(1)</sup>	A	\$5.76	164,547	D	
Common Stock	09/30/2019		P		65 <sup>(1)</sup>	A	\$5.89	164,612	D	
Common Stock	10/01/2019		P		65 <sup>(1)</sup>	A	\$5.89	164,677	D	
Common Stock	10/02/2019		P		65 <sup>(1)</sup>	A	\$5.77	164,742	D	
Common Stock	10/04/2019		P		65 <sup>(1)</sup>	A	\$5.76	164,807	D	
Common Stock	10/07/2019		P		65 <sup>(1)</sup>	A	\$5.74	164,872	D	
Common Stock	10/08/2019		P		65 <sup>(1)</sup>	A	\$5.81	164,937	D	
Common Stock	10/09/2019		P		65 <sup>(1)</sup>	A	\$5.78	165,002	D	
Common Stock	10/10/2019		P		65 <sup>(1)</sup>	A	\$5.86	165,067	D	
Common Stock	10/11/2019		P		65 <sup>(1)</sup>	A	\$5.71	165,132	D	
Common Stock	10/14/2019		P		65 <sup>(1)</sup>	A	\$5.67	165,197	D	
Common Stock	10/15/2019		P		65 <sup>(1)</sup>	A	\$5.63	165,262	D	
Common Stock	10/16/2019		P		65 <sup>(1)</sup>	A	\$5.56	165,327	D	
Common Stock	10/17/2019		P		65 <sup>(1)</sup>	A	\$5.52	165,392	D	
Common Stock	10/18/2019		P		65 <sup>(1)</sup>	A	\$5.45	165,457	D	
Common Stock	10/19/2019		P		38 <sup>(1)</sup>	A	\$5.51	165,495	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

**Explanation of Responses:**

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.

**Remarks:**

Kenneth J. Krogulski by /s/  
Michael Bonner as attorney-in- 10/25/2019  
fact

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**